Biopharmaceuticals firm Biocon has opened a new insulin devices manufacturing facility in Bangalore, India.

The company will use the 100,000ft² facility to manufacture new generation devices for its insulins portfolio.

Biocon chairperson and managing director Kiran Mazumdar-Shaw said: "Our aim is to provide insulin products to at least one in five insulin-dependent diabetes patients, anywhere in the world.

"This new devices facility is a key milestone in our journey towards that goal. It will enable us to not only fulfil our commitment to ‘Make in India for the World’ but also deliver on the promise of ‘Affordable Access to Healthcare for All’."

Biocon has also introduced new Basalog One, a ready-to-use insulin glargine disposable pen for better blood sugar management for people with diabetes.

The insulin pen, which is light weight, easy to carry and disposable, will allow patients to effectively manage their blood sugar levels.

Biocon partnered with US-based medical devices firm Becton Dickinson to customize the design of Basalog One device to enable it to deliver firm’s range of insulin products.

Biocon CEO Dr Arun Chandavarkar said: "India has the potential to become the next global manufacturing hub in biomedical devices and at Biocon, we are committed to explore this potential."

Biocon’s other Basalog portfolio includes vials, refills and reusable devices, which are used as diabetes management solution for people with diabetes.